brolucizumabin

Brolucizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A). It is developed for the treatment of neovascular age-related macular degeneration (nAMD), also known as wet AMD. Brolucizumab is administered via intravitreal injection, meaning it is injected directly into the vitreous humor of the eye. Its mechanism of action involves binding to all isoforms of VEGF-A, thereby inhibiting its activity. VEGF-A plays a crucial role in the development of neovascularization, a process where abnormal blood vessels grow under the retina, leading to leakage and vision loss in wet AMD. By neutralizing VEGF-A, brolucizumab aims to reduce the growth of these abnormal blood vessels and prevent leakage, ultimately preserving or improving visual acuity. It is administered less frequently than some other anti-VEGF therapies. Clinical trials have demonstrated its efficacy in improving vision and reducing retinal edema in patients with nAMD. However, like other intravitreal therapies, potential side effects exist, including ocular inflammation and retinal vasculitis.